MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

MannKind Corp

Closed

SectorHealthcare

5.43 -3.89

Overview

Share price change

24h

Current

Min

5.43

Max

5.71

Key metrics

By Trading Economics

Income

-12M

668K

Sales

-1.8M

77M

P/E

Sector Avg

49

35.739

Profit margin

0.873

Employees

403

EBITDA

-17M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+81.8% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

505M

1.7B

Previous open

9.32

Previous close

5.43

News Sentiment

By Acuity

44%

56%

176 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Oct 2025, 16:58 UTC

Earnings

BMW Trims 2025 View, Citing Weaker Performance in China

7 Oct 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 Oct 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 Oct 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 Oct 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 20:44 UTC

Hot Stocks

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 Oct 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 Oct 2025, 19:23 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 Oct 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 Oct 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 Oct 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 Oct 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 Oct 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 Oct 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 Oct 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 Oct 2025, 14:52 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

81.8% upside

12 Months Forecast

Average 10.29 USD  81.8%

High 15 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

176 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat